Jefferies Financial Group Inc. Invests $753,000 in Evolus, Inc. (NASDAQ:EOLS)

Jefferies Financial Group Inc. bought a new position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 68,181 shares of the company's stock, valued at approximately $753,000. Jefferies Financial Group Inc. owned 0.11% of Evolus as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of EOLS. Tri Locum Partners LP acquired a new stake in shares of Evolus during the fourth quarter worth $8,198,000. Gilder Gagnon Howe & Co. LLC increased its holdings in shares of Evolus by 287.2% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company's stock worth $7,753,000 after acquiring an additional 520,859 shares during the period. Caligan Partners LP increased its holdings in shares of Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock worth $29,724,000 after acquiring an additional 498,900 shares during the period. Allostery Investments LP acquired a new stake in shares of Evolus in the 4th quarter worth about $4,760,000. Finally, Altium Capital Management LLC increased its holdings in shares of Evolus by 93.0% in the 4th quarter. Altium Capital Management LLC now owns 685,000 shares of the company's stock worth $7,562,000 after acquiring an additional 330,000 shares during the period. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Trading Down 0.1%

EOLS stock traded down $0.01 during mid-day trading on Wednesday, reaching $9.95. 138,413 shares of the stock traded hands, compared to its average volume of 687,307. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 52-week low of $8.67 and a 52-week high of $17.82. The company has a market cap of $641.54 million, a P/E ratio of -10.92 and a beta of 1.11. The stock's fifty day moving average is $11.19 and its 200-day moving average is $12.24.

Analysts Set New Price Targets

EOLS has been the topic of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. BTIG Research assumed coverage on shares of Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective on the stock. Barclays increased their target price on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Evolus in a research report on Thursday, May 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Evolus has an average rating of "Buy" and an average price target of $23.75.

Insider Buying and Selling at Evolus

In other news, insider Rui Avelar sold 27,904 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the sale, the insider now directly owns 362,467 shares of the company's stock, valued at $4,806,312.42. This represents a 7.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sandra Beaver sold 8,996 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $119,286.96. Following the completion of the sale, the chief financial officer now directly owns 173,583 shares of the company's stock, valued at $2,301,710.58. This trade represents a 4.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 86,241 shares of company stock valued at $1,048,666. 5.90% of the stock is currently owned by corporate insiders.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.